Fractyl Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GUTS research report →
Range $5 – $5
Price Chart
About the company
Fractyl Health, Inc. , a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
- CEO
- Harith Rajagopalan
- IPO
- 2024
- Employees
- 100
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on GUTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.88M
- P/E
- -0.14
- Fwd P/E
- 0.32
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.82
- EV/EBITDA
- -0.53
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1860.27%
- ROIC
- -150.98%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-96,816,000
- Net Income
- $-140,954,000-105.2%
- EPS
- $-11.04+43.2%
- OCF Growth
- -37.9%
- FCF Growth
- -35.1%
- 52W High
- $29.34
- 52W Low
- $0.78
- 50D MA
- $3.20
- 200D MA
- $6.70
- Beta
- 2.42
- RSI (14)
- 27
- Avg Volume
- 504.39K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Fractyl said REMAIN-1 met its 6-month endpoint, and the company is now focused on a late-2026 de novo filing, 2027 pivotal data, and reducing burn to extend cash runway.· November 12, 2026
- REMAIN-1 met its 6-month co-primary endpoint with high statistical significance (p=0.0023) in a randomized, double-blind sham-controlled study.
- Revita patients kept about 80% of tirzepatide weight loss at 6 months; management said the effect widened over time and looked strongest with longer ablations.
- The company cut about 45% of staff, stopped Rejuva development, and expects quarterly operating cash spending to fall by about half to approximately $8 million by end-Q2 2027.
- Fractyl ended the quarter with $31.5 million in cash and said that is enough to fund operations into Q2 2027 through the de novo submission and 12-month REMAIN-1 data.
- Reimbursement progress included the AMA publishing Category III CPT code 1122T, effective Jan. 1, 2027, and CMS’s proposed Rapid pathway remains an important pending catalyst.
Third-quarter 2026 revenue was not stated. R&D expense was $12.5 million versus $17.5 million a year earlier, and SG&A was $6.2 million versus $5.2 million a year earlier. Net loss was $14.2 million versus $45.6 million in the prior-year quarter, and adjusted EBITDA was negative $16.0 million versus negative $20.8 million. Cash and cash equivalents were $31.5 million at Sept. 30, 2026, and cash used in operations was just below $16 million in the quarter. Guidance: the company expects quarterly operating cash spending to decline by about 50% to approximately $8 million by the end of Q2 2027, with cash sufficient to fund operations into Q2 2027 through the planned de novo submission and anticipated top-line 1-year REMAIN-1 data. Management plans to begin the de novo submission in late Q4 2026, expects 12-month REMAIN-1 top-line data in Q1 2027, and said FDA marketing authorization could come in late 2027 with a potential U.S. launch in early 2028.
Harith Rajagopalan framed Revita as a potential ‘off-ramp’ for patients who stop GLP-1 therapy and regain weight, arguing the problem is biological and rooted in the gut. He emphasized that REMAIN-1 was a rigorous stress test, said the 6-month result supports the platform, and pointed to a dose-response where longer ablations appeared to perform better. His tone was confident and focused on execution, repeatedly stressing the next milestones: de novo submission, 12-month data, and clarity on CMS Rapid.
Lara Weber emphasized discipline and lower spending as the company refocused on Revita. She reported R&D of $12.5 million, SG&A of $6.2 million, a net loss of $14.2 million, adjusted EBITDA of negative $16.0 million, and $31.5 million in cash and cash equivalents at quarter-end. She said cash used in operations was just below $16 million, but after the restructuring the company expects quarterly operating cash spending to fall to about $8 million by the end of Q2 2027, with about $2 million of severance-related charges mostly in Q4.
Analysts focused on the Medicare opportunity, the FDA pathway and class classification, reimbursement timing, and whether longer ablation lengths would require more physician training. Management said Medicare participation is rising quickly in the GLP-1 bridge program and that the company is planning an early launch predicated on Medicare patients; it also said longer ablations add only about 2 minutes per additional 2 centimeters and do not appear to add a safety signal. On the FDA question, management said it has not yet met with the agency post-readout but does not expect a special pre-filing meeting to be required, while the company also addressed a possibly related GI bleed event by saying it believed NSAID use was the more likely cause.
The strongest bull case is that Revita produced a statistically significant 6-month result in a sham-controlled pivotal study, with management saying patients retained about 80% of their prior tirzepatide weight loss. The company also sees a large addressable population of GLP-1 discontinuers, growing Medicare access, and a targeted center-of-excellence launch model that could support commercialization with a relatively small team.
The main risks are that the company still needs 12-month data, a successful de novo filing, and a favorable CMS Rapid decision before any launch can happen. Financially, Fractyl still burns cash and says it will need additional capital beyond the current milestones to bring Revita to market, while the quarter also included a possibly related serious adverse event that analysts pressed management to explain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.0%
- Shares Outstanding
- 13.26M
- Float Shares
- 11.27M
of shares held by institutions
78 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Catalio Capital Management, LP | 8.84M | ▲ 2.67M |
| Vanguard Capital Management LLC | 6.75M | ▲ 654.02K |
| 683 Capital Management, LLC | 6.50M | ▲ 5.74M |
| Vanguard Group Inc | 6.03M | ▲ 4.11M |
| Pale Fire Capital Se | 4.78M | ▼ 220.68K |
| Deer Management Co. LLC | 4.77M | 0 |
| Hcc Manager LLC | 4.67M | ▼ 1 |
| Maverick Capital Ltd | 3.97M | 0 |
| M28 Capital Management LP | 1.86M | 0 |
| Blackrock, Inc. | 1.81M | ▲ 8.76K |
| Brevan Howard Capital Management LP | 1.76M | ▲ 848.04K |
| Woodline Partners LP | 1.64M | ▼ 138.98K |
Held by 22 ETFs
Biggest fund positions in GUTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Wartell Michael J. | other | 0 |
| Sep 14, 26 | BRADLEY WILLIAM | buy | 64,516 |
| Jun 12, 26 | Royan Ajay | buy | 23,000 |
| Jun 10, 26 | BRADLEY WILLIAM | buy | 68,493 |
| Jun 10, 26 | BRADLEY WILLIAM | other | 22,500 |
| Jun 10, 26 | Conaway Samuel | other | 22,500 |
| Jun 10, 26 | Royan Ajay | other | 22,500 |
| Jun 10, 26 | Thompson Christopher Charles | other | 22,500 |
| Jun 10, 26 | Elia Marc | other | 22,500 |
| Jun 10, 26 | Barnes Kelly Ann | other | 22,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GUTS coverage
Recent articles, reports, and earnings notes.
No research on GUTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GUTS report →Fractyl Health, Inc. (GUTS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Fractyl Health Reports Third Quarter 2026 Financial Results and Business Updates
globenewswire.com · Nov 12
Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Consensus Price Target of $50.25 According to Brokerages
defenseworld.net · Nov 10
Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
globenewswire.com · Nov 6
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
globenewswire.com · Oct 30
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
globenewswire.com · Oct 29
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
globenewswire.com · Oct 22
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS
globenewswire.com · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.